Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague) in collaboration with Institute of Physiology of the CAS developed new compounds with positive effects in experimental animal models of obesity and type II diabetes.

Compounds were developed in the laboratory of Dr. Lenka Maletínská (IOCB Prague) whose team focused on synthesis and study of modified analogues of endogenous neuropeptides. In cooperation with Dr. Kuneš (Dept. Experimental Hypertension, IP AS CR) these compounds are tested in various models of rats and mice.

Both Institutes have signed research collaborative and license agreements with major pharmaceutical company Novo Nordisk which will develop and prepare these compounds for preclinical testing on animal models followed by clinical trials if successful.